The methylenetetrahydrofolate reductase C677T gene mutation is associated with hyperhomocysteinemia, cardiovascular disease and plasma B-type natriuretic peptide levels in Korea

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 9, 2006, Pages 1070-1075

  Sung, Eun Cho ^a   Ki, Sook Hong ^a   Gil, Ja Shin ^a   Wha, Soon Chung ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

B type natriuretic peptide (BNP); Cardiovascular diseases; Homocysteine; MTHFR

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATINE KINASE; CREATININE; FOLIC ACID; LACTATE DEHYDROGENASE; TROPONIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ELECTROPHORESIS; FEMALE; GENE MUTATION; GENOTYPE; HOMOZYGOTE; HUMAN; HYPERHOMOCYSTEINEMIA; KOREA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CREATINE KINASE; CREATININE; FEMALE; FOLIC ACID; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; ISOENZYMES; KOREA; L-LACTATE DEHYDROGENASE; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; NATRIURETIC PEPTIDE, BRAIN; TROPONIN I;

EID: 33748546300     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2006.194     Document Type: Article

References (36)

1. Oh GY, Lee GI, Hong KS, Chung IM. Hyperhomocysteinemia as a risk factor for coronary artery disease. Korean J Lab Med 2002;22:131-7.
2. Stampfer MJ, Malinow MR, Willet WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992;268:877-81.
3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995;274:1049-57.
4. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991;48:536-45.
5. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc 1993;270:2693-8.
6. Girelli D, Martinelli N, Pizzolo F, Friso S, Olivieri O, Stranieri C, et al. The interaction between MTHFR 677 C → T genotype and folate status is a determinant of coronary atherosclerosis risk. J Nutr 2003;133:1281-5.
7. Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995;56:142-50.
8. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
9. Dunn J, Title LM, Bata I, Johnstone DE, Kirkland SA, O'Neill BJ, et al. Relation of a common mutation in methylenetetrahydrofolate reductase to plasma homocysteine and early onset coronary artery disease. Clin Biochem 1998;31:95-100.
10. Payne DA, Chamoun AJ, Seifert SL, Stouffer GA. MTHFR 677 C → T mutation: a predictor of early-onset coronary artery disease risk. Thromb Res 2001;103:275-9.
11. Mager A, Lalezari S, Shohat T, Birnbaum Y, Adler Y, Magal N, et al. Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease. Circulation 1999;100:2406-10.
12. Ravera M, Viazzi F, Berruti V, Leoncini G, Zagami P, Bezante GP, et al. 5,10-Methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension. Am J Hypertens 2001;14:371-6.
13. Pisciotta L, Cortese C, Gnasso A, Liberatoscioli L, Pastore A, Mannucci L, et al. Serum homocysteine, methylenetetrahydrofolate reductase gene polymorphism and cardiovascular disease in heterozygous familial hypercholesterolemia. Atherosclerosis 2005;179:333-8.
14. Wiese S, Breyer T, Dragu A, Wakili R, Burkard T, Schmidt-Schweda S, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 2000;102:3074-9.
15. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
16. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464-9.
17. Magga J, Vuolteenaho O, Tokola H, Marttila M, Ruskoaho H. B-Type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Ann Med 1998;30:39-45.
18. De Lemos JA, McGuire DK, Drazner MH. B-Type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-22.
19. Cho SE, Shin GJ, Hong KS. Evaluation of the B-type natriuretic peptide level in identifying patients with cardiovascular diseases in South Korea. Point of Care 2005;4:15-9.
20. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine concentration and its relation to symptoms of vascular disease in psychogeriatric patients. Dement Geriatr Cogn Disord 2005;20:35-41.
21. Hong SC, Ann JY, Cho SJ, Chung CS, Lee KH, Hong SC, et al. A case of cerebellar hemorrhage associated with hyperhomocysteinemia. J Korean Neurol Assoc 1999;17:407-11.
22. Zetterberg H. Methylenetetrahydrofolate reductase and transcobalamin genetic polymorphisms in human spontaneous abortion: biological and clinical implications. Reprod Biol Endocrinol 2004;2:7.
23. Ulvik A, Vollset SE, Hansen S, Gislefoss R, Jellum E, Ueland PM. Colorectal cancer and the methylenetetrahydrofolate reductase 677C → T and methionine synthase 2756A → G polymorphisms: a study of 2168 case-control pairs from the JANUS cohort. Cancer Epidemiol Biomarkers Prev 2004;13:2175-80.
24. Kim CH, Hwang KY, Choi TM, Shin WY, Hong SY. The methylenetetrahydrofolate reductase gene polymorphism in Koreans with coronary artery disease. Int J Cardiol 2001;78:13-7.
25. Huh HJ, Chi HS, Shim EH, Jang S, Park CJ. Gene-nutrition interactions in coronary artery disease: correlation between the MTHFR C677T polymorphism and folate and homocysteine status in a Korean population. Thromb Res 2006;117:501-6.
26. Lwin H, Yoshiike N, Yokoyama T, Saito K, Date C, Tanaka H. The relationships between plasma total homocysteine and selected atherosclerotic risk factors according to the C677T methylenetetrahydrofolate reductase gene in Japanese. Eur J Cardiovasc Prev Rehabil 2005;12:182-4.
27. Shioji K, Kokubo Y, Goto Y, Nonogi H, Iwai N. An association analysis between genetic polymorphisms of matrix metalloproteinase-3 and methylenetetrahydrofolate reductase and myocardial infarction in Japanese. J Thromb Haemost 2004;2:527-8.
28. Angeline T, Jeyaraj N, Granito S, Tsongalis GJ. Prevalence of MTHFR gene polymorphisms (C677T and A1298C) among Tamilians. Exp Mol Pathol 2004;77:85-8.
29. Heux S, Morin F, Lea RA, Ovcaric M, Tajouri L, Griffiths LR. The methylenetetrahydrofolate reductase gene variant (C677T) as a risk factor for essential hypertension in Caucasians. Hypertens Res 2004;27:663-7.
30. Esfahani ST, Cogger EA, Caudill MA. Heterogeneity in the prevalence of methylenetetrahydrofolate reductase gene polymorphisms in women of different ethnic groups. J Am Diet Assoc 2003;103:200-7.
31. Herrmann W, Obeid R, Hubner U, Jouma M, Geisel J. Homocysteine in relation to C-reactive protein and low-density lipoprotein cholesterol in assessment of cardiovascular risk. Cell Mol Biol (Noisy-le-grand) 2004;50:895-901.
32. Husemoen LL, Thomsen TF, Fenger M, Jorgensen HL, Jorgensen T. Contribution of thermolabile methylenetetrahydrofolate reductase variant to total plasma homocysteine levels in healthy men and women. Inter99 (2). Genet Epidemiol 2003;24:322-30.
33. Pathare A, Alkindi S, Albalushi T, Bayoumi R, Dennison D, Muralitharan S. Heterozygous methylenetetrahydrofolate reductase mutation with mild hyperhomocysteinemia associated with deep vein thrombosis. Clin Lab Haematol 2004;26:143-6.
34. Herrmann M, Kindermann I, Muller S, Georg T, Kindermann M, Bohm M, et al. Relationship of plasma homocysteine with the severity of chronic heart failure. Clin Chem 2005;51:1512-5.
35. Sundstrom J, Vasan RS. Homocysteine and heart failure: a review of investigations from the Framingham Heart Study. Clin Chem Lab Med 2005;43:987-92.
36. Kimura Y, Takamura N, Fukunaga M, Kanagae M, Abe Y, Aoyagi K. Evaluation of high sensitive C-reactive protein and 5-10 methylenetetrahydrofolate reductase genotype in Japanese young adults. Biomarkers 2004;9:291-7.